FLT3 internal tandem duplication during myelodysplastic syndrome follow-up: a marker of transformation to acute myeloid leukemia
- 作者：Ronald Feitosa Pinheiro ; Eloisa de Sá ; Moreira ; Maria Regina Ré ; gis Silva ; Fern ; o Lopes Alberto ; Maria de Lourdes L.F. Chauffaille
- 关键词：Nonlinear energy sink ; Strongly modulated response ; Relaxation oscillations
- 刊名：Cancer Genetics and Cytogenetics
- 出版年：2008
- 期刊代码：43_01654608
- 类别：med
- 出版时间：June 2008
- 卷：183
- 期：2
- 页码：89-93
- 文件大小：279 K
摘要
Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disorder characterized by ineffective hematopoiesis and risk for evolving to acute leukemia. Some molecular abnormalities related to acute myeloid leukemia (AML) transformation have been reported, such as FLT3 (FMS-like tyrosine kinase 3) mutations. FLT3, a member of the class 3 receptor tyrosine kinase family, mediates stem cell proliferation and differentiation, and its mutations, internal tandem duplication (ITD) and Asp835, have been reported in rare MDS patients. We studied FLT3 ITD, prospectively, in 50 MDS patients at diagnosis, at 6 and 12 months follow-up, and at any other time-point if AML transformation was detected. FLT3 ITD was not observed at diagnosis, but during follow-up the mutation was present in 2 of 50 patients (4%). Of these, one case exhibited FLT3 ITD at the end of the 6 months of follow-up in 
8%of bone marrow cells; this case evolved into AML at 8 months, at which time FLT3 ITD was present in 85%of bone marrow cells. The other case exhibited FLT3 ITD in 68%of bone marrow cells at 7 months, precisely at the time of AML transformation. Although rare in MDS, FLT3 ITD is associated with a high probability of evolution to AML.
8%of bone marrow cells; this case evolved into AML at 8 months, at which time FLT3 ITD was present in 85%of bone marrow cells. The other case exhibited FLT3 ITD in 68%of bone marrow cells at 7 months, precisely at the time of AML transformation. Although rare in MDS, FLT3 ITD is associated with a high probability of evolution to AML.